The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 5 briefings matching “kidney”

Reset all filters

Cardiology

Cardiology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo (inactive comparison treatment), highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and risk of death in this high-risk population. This was a prespecified secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, conducted from June 2019 to September 2024 with a median (IQR) follow-up of 49.5 (44.0-54.9) months at 444 centers in 33 countries.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMA CardiologyNov 11, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

Dapagliflozin for Renal Protection in Heart Transplant Recipients: A Randomized Clinical Trial

In heart transplant recipients, dapagliflozin, compared with placebo (inactive comparison treatment), improved the slope of the eGFR from 2 weeks to 12 months of treatment. Progressive kidney disease is common in heart transplant recipients due to calcineurin inhibitor exposure and pre-existing comorbidities.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readCirculationNov 8, 2026

CARDIOLOGY · CLINICAL PRACTICE

Interpreting High-Sensitivity Cardiac Troponin in Clinical Practice and Emerging Directions: Detection Is No Longer Diagnosis

Until then, that burden rests with the clinician. Finally, we review emerging understanding of troponin biology, clearance, proteolysis and fragmentation, macrotroponin, antitroponin autoantibodies, and extracellular vesicle-associated troponin, which may eventually allow the assay itself to carry more of the interpretive burden.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readJournal of the American College of CardiologyOct 28, 2026

CARDIOLOGY · REAL-WORLD COHORT

Cortisol in cardio-kidney-metabolic disease

This review will serve as a practical guide for cardiologists to manage a potentially reversible contributor to poor CKM control. Therapeutic strategies include adrenal steroidogenesis inhibitors, glucocorticoid receptor antagonists, and pituitary-directed therapies in selected cases, while surgery remains the first-line treatment for surgically remediable disease.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readEuropean Heart JournalOct 28, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

Individualized Cardiac Index-Guided Hemodynamic Therapy in High-Risk Patients Undergoing Elective Major Abdominal Surgery: The PELICAN Randomized Clinical Trial

Among high-risk patients undergoing elective major abdominal surgery, individualized cardiac index-guided hemodynamic therapy targeting the patient's preoperative resting cardiac index did not reduce the incidence of a composite outcome of acute kidney injury, acute myocardial injury, severe infectious complications, nonfatal cardiac arrest, or death within the first 7 postoperative days compared with routine hemodynamic therapy. It remains unclear if intraoperative hemodynamic therapy should be guided by cardiac index.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMAOct 19, 2026

Interactive Fact Check